How effective is Eltrombopag/Eltrombopag treatment?

Eltrombopag is a thrombopoietin receptor agonist widely used to treat different types of thrombocytopenia, including chronic immune (idiopathic) thrombocytopenia (ITP), hepatitis C-associated thrombocytopenia, and severe aplastic anemia (AA). Its effectiveness and safety in clinical practice have been verified by multiple studies.

1. Treatment of chronic immune (idiopathic) thrombocytopenia (ITP)

Studies in adults ITP patients have shown that eltrombopag is effective in improving platelet counts. The two major studies involved a total of 311 patients who had previously received treatments that failed to effectively control their disease. In the first study, after six weeks of treatment, 59% of patients in the eltrombopag group had platelet counts above 50,000 per microliter, compared with 16% of patients in the placebo group. The second study showed that within 6 months of treatment, 135 patients in the eltrombopag group were about eight times more likely to achieve target platelet counts than 62 patients in the placebo group. In addition, an analytical study examined the impact of time to diagnosis on drug response and found that patients with early or late diagnosis had similar rates of reaching a platelet count of 50,000/microliter after treatment.

Eltrombopag also shows good results in the treatment of children with ITP. One study involving 92 children aged 1 to 17 years showed that without rescue medication, 40% of patients in the eltrombopag group experienced an increase in platelet counts of at least 50,000 per microliter during treatment, compared with only 3% in the placebo group. This shows that eltrombopag is also very effective in pediatric patients and can effectively maintain adequate platelet levels.

2. Hepatitis C-associated thrombocytopenia

The study of patients with hepatitis C consisted of two major trials, with a total of 1,441 adults participating. The study focused on comparing eltrombopag with placebo in initiating and maintaining antiviral therapy. Because patients with hepatitis C often have low platelet counts and have difficulty initiating antiviral treatment, increasing platelet counts has become a research goal. The results showed that the proportion of patients taking eltrombopag who tested negative for hepatitis C was significantly higher than the placebo group, 23% vs. 14% in the first study and 19% vs. 13% in the second study. This suggests that eltrombopag not only improves platelet counts but also improves the success of antiviral treatment.

3. Severe aplastic anemia (AA)

Eltrombopag’s efficacy has also been initially recognized in the treatment of severe aplastic anemia. One item containsThe 43-patient study evaluated its effectiveness, with the primary metric being the number of patients whose platelet, red blood cell or white blood cell counts remained at a set level after 12 or 16 weeks of treatment. The results showed that 40% of patients responded to treatment after 12 weeks, with 65% of patients having platelet counts that increased by at least 20,000 per microliter or remained stable without the need for transfusions. In addition, preliminary data from a supporting study also showed that 46% of patients responded to treatment after 12 weeks, consistent with the main study results.

In summary, eltrombopag has shown good efficacy in the treatment of different types of thrombocytopenia. By increasing platelet count, it not only helps ITP patients improve their condition, but also provides a possible solution for antiviral treatment of hepatitis C patients. It also shows potential in the management of severe aplastic anemia.

Reference materials:https://go.drugbank.com/drugs/DB06210